ICYMI: EI-1071 for IPF Earns Orphan Drug Status
Sourced from: James Heilman, MD / CC BY-SA (https://creativecommons.org/licenses/by-sa/3.0)

ICYMI: EI-1071 for IPF Earns Orphan Drug Status

  According to an August 2022 news release from biotechnology company Elixiron Immunotherapeutics (“Elixiron”), EI-1071, a therapy for patients with idiopathic pulmonary fibrosis (IPF), recently earned Orphan Drug designation from…

Continue Reading ICYMI: EI-1071 for IPF Earns Orphan Drug Status
Phase 2b Global Trial for Idiopathic Pulmonary Fibrosis Has Completed Enrollment
https://pixabay.com/en/hand-world-ball-keep-child-earth-644145/

Phase 2b Global Trial for Idiopathic Pulmonary Fibrosis Has Completed Enrollment

Galecto has announced they have completed enrollment in their Phase2b trial which will investigate GB0139 as a treatment for idiopathic pulmonary fibrosis (IPF). This trial is called GALACTIC-1. Galecto anticipates…

Continue Reading Phase 2b Global Trial for Idiopathic Pulmonary Fibrosis Has Completed Enrollment

European Study Demonstrates Need for Faster Diagnosis and Improved Counseling for Pulmonary Fibrosis Patients

A recent study has uncovered just how many people with pulmonary fibrosis (PF) do not receive an immediate diagnosis. This study conducted in Europe was published in Frontiers of Medicine.…

Continue Reading European Study Demonstrates Need for Faster Diagnosis and Improved Counseling for Pulmonary Fibrosis Patients
Idiopathic Pulmonary Fibrosis: Antifibrotic Therapy Can Curb Exacerbations and Mortality
source: pixabay.com

Idiopathic Pulmonary Fibrosis: Antifibrotic Therapy Can Curb Exacerbations and Mortality

According to a story on medicaldialogues.in, a recent study has determined that antifibrotic treatment can reduce the rate of mortality and acute exacerbations in people living with idiopathic pulmonary fibrosis…

Continue Reading Idiopathic Pulmonary Fibrosis: Antifibrotic Therapy Can Curb Exacerbations and Mortality
Collaborative Study Provides Increased Understanding of Idiopathic Pulmonary Fibrosis
source: pixabay.com

Collaborative Study Provides Increased Understanding of Idiopathic Pulmonary Fibrosis

A study conducted by researchers at Nagoya University in Japan and researchers from Yale University in the United States was recently published in the European Respiratory Journal.  This study utilized single-cell…

Continue Reading Collaborative Study Provides Increased Understanding of Idiopathic Pulmonary Fibrosis
VerSIM Life Launched A Pharmaceutical Branch With A Rare Disease Mission
source: pixabay.com

VerSIM Life Launched A Pharmaceutical Branch With A Rare Disease Mission

As reported in Business Wire; VerSIM Life, a company that uses computational sciences to create novel machine learning to aid drug development, has announced that they are launching a pharmaceutical…

Continue Reading VerSIM Life Launched A Pharmaceutical Branch With A Rare Disease Mission
There’s a New Molecular Target for IPF, Research Shows
Sourced from: James Heilman, MD / CC BY-SA (https://creativecommons.org/licenses/by-sa/3.0)

There’s a New Molecular Target for IPF, Research Shows

An estimated 13-20 out of every 100,000 people around the globe have idiopathic pulmonary fibrosis (IPF). The condition often has a poor prognosis (3-5 years following diagnosis) and there are…

Continue Reading There’s a New Molecular Target for IPF, Research Shows

Researchers Work to Understand the Role of GDF15 in Lung Diseases Like Idiopathic Pulmonary Fibrosis

Growth differentiation factor 15 (GDF15) is expressed in normal conditions but is overly expressed when cells are under stress. It has multiple roles in different diseases and has been used…

Continue Reading Researchers Work to Understand the Role of GDF15 in Lung Diseases Like Idiopathic Pulmonary Fibrosis
Findings From This Phase 2 Idiopathic Pulmonary Fibrosis Trial Look Promising
source: pixabay.com

Findings From This Phase 2 Idiopathic Pulmonary Fibrosis Trial Look Promising

According to a story from GlobeNewswire, the biotechnology company Galecto, Inc., has recently published the results from its phase 2a clinical trial. This study was testing the company's experimental therapy…

Continue Reading Findings From This Phase 2 Idiopathic Pulmonary Fibrosis Trial Look Promising
Presentation: Tyvaso as a Treatment for Interstitial Lung Disease
source: pixabay.com

Presentation: Tyvaso as a Treatment for Interstitial Lung Disease

United Therapeutics Corporation has recently presented data from the Phase 3 INCREASE trial, which evaluated Tyvaso as a treatment for pulmonary hypertension associated with interstitial lung disease. Results were presented…

Continue Reading Presentation: Tyvaso as a Treatment for Interstitial Lung Disease
Idiopathic Pulmonary Fibrosis Treatment Does Well In Preclinical Trial
source: pixabay.com

Idiopathic Pulmonary Fibrosis Treatment Does Well In Preclinical Trial

Cynata Therapeutics Limited has recently announced the results from their preclinical trial of induced pluripotent stem cell (iPSC)-derived Cymerus™ mesenchymal stem cells (MSCs), according to BioSpace. They are testing these…

Continue Reading Idiopathic Pulmonary Fibrosis Treatment Does Well In Preclinical Trial
September is Pulmonary Fibrosis Awareness Month: Spreading Rare Disease Awareness
source: pixabay.com

September is Pulmonary Fibrosis Awareness Month: Spreading Rare Disease Awareness

According to a story from Newswise, September is recognized as Pulmonary Fibrosis Awareness Month. This includes idiopathic pulmonary fibrosis (IPF), or disease without an identifiable cause. In the midst of…

Continue Reading September is Pulmonary Fibrosis Awareness Month: Spreading Rare Disease Awareness